Emerging roles of kisspeptin/galanin in age-related metabolic disease.


Journal

Mechanisms of ageing and development
ISSN: 1872-6216
Titre abrégé: Mech Ageing Dev
Pays: Ireland
ID NLM: 0347227

Informations de publication

Date de publication:
10 2021
Historique:
received: 27 06 2021
revised: 08 07 2021
accepted: 07 09 2021
pubmed: 14 9 2021
medline: 19 2 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

Age is a major risk factor for developing metabolic diseases such as obesity and diabetes. There is an unprecedented rise in obesity and type 2 diabetes in recent decades. A convincing majority of brain-gut peptides are associated with a higher risk to develop metabolic disorders, and may contribute to the pathophysiology of age-related metabolic diseases. Accumulating basic studies revealed an intriguing role of kisspeptin and galanin involved in the amelioration of insulin resistance in different ways. In patients suffered from obesity and diabetes a significant, sex-related changes in the plasma kisspeptin and galanin levels occurred. Kisspeptin is anorexigenic to prevent obesity, its level is negatively correlative with obesity and insulin resistance. While galanin is appetitive to stimulate food intake and body weight, its level is positively correlative with obesity, HOMA-IR and glucose/triglyceride concentration. In turn, kisspeptin and galanin also distinctly increase glucose uptake and utilization as well as energy expenditure. This article reviews recent evidence dealing with the role of kisspeptin and galanin in the pathophysiology of age-related metabolic diseases. It should be therefore taken into account that the targeted modulation of those peptidergic signaling may be potentially helpful in the future treatment of age-related metabolic diseases.

Identifiants

pubmed: 34517021
pii: S0047-6374(21)00143-3
doi: 10.1016/j.mad.2021.111571
pii:
doi:

Substances chimiques

Kisspeptins 0
Galanin 88813-36-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

111571

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Penghua Fang (P)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Department of Physiology, Nanjing University of Chinese Medicine Hanlin College, Taizhou, 225300, China. Electronic address: fphlcollegesci@njucm.edu.cn.

Yuqing She (Y)

Department of Endocrinology, Pukou Branch of Jiangsu People's Hospital, Nanjing, 210023, China.

Juan Zhao (J)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Jing Yan (J)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Xizhong Yu (X)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Yu Jin (Y)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Qingbo Wei (Q)

Key Laboratory of Acupuncture and Medicine Research of Minister of Education, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Zhenwen Zhang (Z)

Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou, 225001, China. Electronic address: zwzhang@yzu.edu.cn.

Wenbin Shang (W)

Key Laboratory for Metabolic Diseases in Chinese Medicine, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Electronic address: wbshang@njucm.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH